Bibliothèque de L'IMIST/CNRST

Includes bibliographical references and index.

For this volume of Advances in Pharmacology we have brought together some of the foremost basic science and clinical researchers to discuss some of the new frontiers in the development of targeted cancer therapy. Although still in its formative stages, the development of targeted cancer therapies has already shown incredible promise in a limited number of cancer types. As basic cancer research and drug development continues, we expect this number to grow and more patients to benefit from these exciting advances. Through better patient selection and novel strategies to manage resistance, a future can be envisaged in which cancer can be reduced to the level of a chronic, manageable disease. Brought together some of the foremost basic science and clinical researchers. Part of the renowned Advances in Pharmacology Serial Discussion of some of the new frontiers in the development of targeted cancer therapy.

Machine generated contents note: 1.Vertical Pathway Targeting in Cancer Therapy / Harriet M. Kluger -- 1.Introduction -- 2.Mitogenic Signaling in Cancer -- 3.Monoclonal Antibodies and Small Molecule Inhibitors Targeting Oncogenic Signaling in Cancer -- 4.Targeting of Parallel Signaling Pathways -- 5.Vertical Pathway Targeting -- 6.Conclusion -- References -- 2.Histone Deacetylases (HDACs) as Mediators of Resistance to Apoptosis in Melanoma and as Targets for Combination Therapy with Selective BRAF Inhibitors / Peter Hersey -- 1.Introduction -- 2.HDACs in Melanoma -- 3.HDACs as Suppressors of Apoptosis -- 4.HDAC Inhibitors Reverse Resistance of Melanoma Cells to Induction of Apoptosis by Selective BRAF Inhibitors -- 5.Reversal of Resistance to PLX4720 is Associated with Changes in the BCL-2 Family Proteins -- 6.Pan-HDAC Inhibitors Reverse the Resistance of Melanoma Cell Lines to Selective BRAF inhibitors: Multispecific versus Specific Agents in Reversal of Resistance to Selective BRAF Inhibitors -- 7.Conclusion -- Acknowledgments -- Abbreviations -- References -- 3.Targeting the Tumor Stroma as a Novel Treatment Strategy for Breast Cancer: Shifting from the Neoplastic Cell-Centric to a Stroma-Centric Paradigm / Jose Conejo-Garcia -- 1.Introduction -- 2.Exploiting the Multifaceted Roles of CAF in Tumor Progression in Development of Novel Therapeutic Strategies for TNBC -- 3.Future CAF Targeting Strategies -- 4.Conclusion -- Acknowledgments -- Abbreviations -- References -- 4.Targeting the Metabolic Microenvironment of Tumors / Robert J. Gillies -- 1.Introduction -- 2.Imaging the Tumor Microenvironment -- 3.Targeting Glucose Metabolism -- 4.Targeting Hypoxia -- 5.Targeting Acidosis -- 6.Manipulating the Microenvironment for Therapeutic Benefit -- 7.Conclusion -- Acknowledgments -- Non-standard abbreviations -- References -- 5.Targeted Therapy for Brain Metastases / Michael A. Davies -- 1.Introduction -- 2.Lung Cancer -- 3.Breast Cancer -- 4.Melanoma -- 5.Conclusion -- Acknowledgments -- Abbreviations -- References -- 6.Emerging Strategies for Targeting Cell Adhesion in Multiple Myeloma / Lori A. Hazlehurst -- 1.Introduction -- 2.Role of Adhesion in MM Disease Progression -- 3.Therapies Targeting Cell Adhesion -- 4.Conclusion -- Acknowledgments -- Abbreviations -- References -- 7.Targeting Notch Signaling for Cancer Therapeutic Intervention / Zhao-Jun Liu -- 1.Introduction -- 2.Notch Signaling in Cancer -- 3.Notch Pathway as Potential Therapeutic Targets in Cancer -- 4.Conclusion -- Acknowledgments -- Abbreviations -- Reference -- 8.Stem-Like Cells and Therapy Resistance in Squamous Cell Carcinomas / Devraj Basu -- 1.Introduction -- 2.CSCS -- 3.CSCS in SCCs -- 4.Epithelial to Mesenchymal Transition and Sternness in SCCs -- 5.Therapy Resistance in CSCs -- 6.CSCs in SCC Clinical Samples and Prognosis -- 7.Discussion -- 8.Conclusion -- Acknowledgments -- Abbreviations -- References -- 9.Targeting the Tumor Stroma as a Novel Therapeutic Approach for Prostate Cancer / Simon W. Hayward -- 1.Introduction -- 2.CAF Taxonomy -- 3.Myofibroblast Conversion During Normal and Pathological Conditions -- 4.CAF Heterogeneity -- 5.Targeting the Inductive Properties of CAF -- 6.Conclusion -- Abbreviations -- References -- 10.Resistance to Chemotherapy. Short-Term Drug Tolerance and Stem Cell-Like Subpopulations / Andrew E. Aplin -- 1.Introduction -- 2.Long-Term Mechanisms of Resistance to Targeted Therapy -- 3.Resistance of Stem Cell-Like Subpopulations -- 4.Plasticity of Transiently Drug-Tolerant Subpopulations -- 5.Potential Strategies to Treat Drug-Tolerant Subpopulations -- 6.Conclusion -- Acknowledgments -- Abbreviations -- References -- 11.Intratumoral Heterogeneity as a Therapy Resistance Mechanism: Role of Melanoma Subpopulations / Meenhard Herlyn -- 1.Introduction -- 2.Molecular Overview of Melanoma -- 3.Therapeutic Overview -- 4.Therapy Resistance -- 5.Tumor Heterogeneity and Melanoma Subpopulations: Their Role in Therapy Resistance -- 6.New Approaches to Therapy -- 7.Future Directions -- 8.Conclusion -- Acknowledgments -- Abbreviations -- References -- 12.Chemoprevention of Melanoma / Gavin P. Robertson -- 1.Introduction -- 2.Melanoma Models for Studying the Efficacy of Chemopreventive Agents -- 3.Chemopreventive Agents that have been Tested for Preventing Melanomas -- 4.Conclusion -- Acknowledgments -- Abbreviations -- References -- 13.Whole Genome and Exome Sequencing of Melanoma: A Step Toward Personalized Targeted Therapy / Nicholas K. Hayward -- 1.Introduction -- 2.Melanoma Genetics -- 3.Personalized Therapeutics -- 4.Conclusion -- Acknowledgments -- Abbreviations -- References -- 14.Targeted Therapy for Gastric Adenocarcinoma / Khaldoun Almhanna -- 1.Introduction -- 2.Molecular Targets in Gastric Cancer -- 3.Conclusion 459 Abbreviations 461 References -- 15.HSP90 Inhibitors for Cancer Therapy and Overcoming Drug Resistance / Shanu Modi -- 1.Introduction -- 2.Clinical Development of HSP90 Inhibitors -- 3.Development of Biomarkers and/or Companion Diagnostic Assays -- 4.Conclusion -- Acknowledgments -- Abbreviations -- References -- 16.Apoptosis In Targeted Therapy Responses: The Role of BIM / Jeffrey A. Engelman -- 1.Introduction -- 2.Background -- 3.Consequences of Oncogene Inhibition in Oncogene-Addicted Cancers -- 4.BIM -- 5.BH3 Profiling -- 6.Cellular Mechanisms That Reduce BIM in Cancers -- 7.Alternative Therapies to Overcome Low BIM Expression -- 8.Conclusion -- Acknowledgments -- Abbreviations -- References.